Adele Caldarella1, Alessandro Barchielli2. 1. Clinical Epidemiology, Institute for Study and Cancer Prevention, via Cosimo il Vecchio 2, 50141, Florence, Italy. a.caldarella@ispo.toscana.it. 2. Clinical Epidemiology, Institute for Study and Cancer Prevention, via Cosimo il Vecchio 2, 50141, Florence, Italy.
Abstract
PURPOSE: The role of progesterone (PR) expression in the management of breast cancer is controversial. The aim of this study is to evaluate the characteristics and prognosis of progesterone status among breast cancers patients in a population-based analysis. MATERIALS AND METHODS: Through the Tuscan Cancer Registry data on all the invasive breast cancer cases diagnosed during the period 2004-2005 in the provinces of Florence and Prato, central Italy, were retrieved. Histological reports were re-examined to obtain information on the percentage of positive tumor cells for estrogen (ER), progesterone (PR) receptors, Ki67 marker and human epidermal growth factor 2 (HER2). Information on age, stage, differentiation grade were also obtained. RESULTS: Out of 1487 patients, 28% had PR- breast cancer. These patients were older (p 0.006) than PR+ cancer patients, with more frequently high Ki67 (p < 0.0001), HER2 + (p < 0.0001), ER- (p < 0.0001) tumoral expression. The ER+/PR+ subtype was the most represented (n.1053), while ER-/PR+ was the most rare (n.23); 210 cases (14.1%) ER+ PR- and 201 (13.5%) ER-/PR- cases were found. Analysis of survival by the Cox proportional hazards model showed an independent prognostic value of PR expression (p < 0.0001), also when estrogen, Ki67, HER2 status and age were included. The 5-year cancer-specific survival was 82.1, 86.5, 100, 92% for ER-/PR-, ER+/PR-, ER-/PR+, ER+/PR+ subtype, respectively. CONCLUSIONS: Our study revealed significant differences in clinicopathological characteristics among breast cancer according to PR expression and confirmed its prognostic independent role, suggesting a role of PR in the improvement of breast cancer prognostic characterization.
PURPOSE: The role of progesterone (PR) expression in the management of breast cancer is controversial. The aim of this study is to evaluate the characteristics and prognosis of progesterone status among breast cancerspatients in a population-based analysis. MATERIALS AND METHODS: Through the Tuscan Cancer Registry data on all the invasive breast cancer cases diagnosed during the period 2004-2005 in the provinces of Florence and Prato, central Italy, were retrieved. Histological reports were re-examined to obtain information on the percentage of positive tumor cells for estrogen (ER), progesterone (PR) receptors, Ki67 marker and human epidermal growth factor 2 (HER2). Information on age, stage, differentiation grade were also obtained. RESULTS: Out of 1487 patients, 28% had PR- breast cancer. These patients were older (p 0.006) than PR+ cancerpatients, with more frequently high Ki67 (p < 0.0001), HER2 + (p < 0.0001), ER- (p < 0.0001) tumoral expression. The ER+/PR+ subtype was the most represented (n.1053), while ER-/PR+ was the most rare (n.23); 210 cases (14.1%) ER+ PR- and 201 (13.5%) ER-/PR- cases were found. Analysis of survival by the Cox proportional hazards model showed an independent prognostic value of PR expression (p < 0.0001), also when estrogen, Ki67, HER2 status and age were included. The 5-year cancer-specific survival was 82.1, 86.5, 100, 92% for ER-/PR-, ER+/PR-, ER-/PR+, ER+/PR+ subtype, respectively. CONCLUSIONS: Our study revealed significant differences in clinicopathological characteristics among breast cancer according to PR expression and confirmed its prognostic independent role, suggesting a role of PR in the improvement of breast cancer prognostic characterization.
Entities:
Keywords:
Breast cancer; Cancer registry; Hormone receptor; Population based; Survival
Authors: Giuseppe Bogina; Gianluigi Lunardi; Francesca Coati; Giuseppe Zamboni; Stefania Gori; Laura Bortesi; Marcella Marconi; Paola Agnese Cassandrini; Monica Turazza; Laura Cortesi; Elisabetta DeMatteis; Guido Ficarra; Toni Ibrahim; Patrizia Serra; Laura Medri; Sara Giraudi; Matteo Lambertini; Franca Carli; Jennifer Foglietta; Angelo Sidoni; Martina Nunzi; Corrado Ficorella; Maria Rosaria Diadema; Lucia Del Mastro Journal: Tumori Date: 2015-05-22 Impact factor: 2.098
Authors: Aleix Prat; Maggie Chon U Cheang; Miguel Martín; Joel S Parker; Eva Carrasco; Rosalía Caballero; Scott Tyldesley; Karen Gelmon; Philip S Bernard; Torsten O Nielsen; Charles M Perou Journal: J Clin Oncol Date: 2012-12-10 Impact factor: 44.544
Authors: Gábor Cserni; Monika Francz; Endre Kálmán; Gyöngyi Kelemen; Detre Csaba Komjáthy; Ilona Kovács; Janina Kulka; László Sarkadi; Nóra Udvarhelyi; László Vass; András Vörös Journal: Pathol Oncol Res Date: 2011-01-26 Impact factor: 3.201
Authors: Werner Schroth; S Winter; F Büttner; S Goletz; S Faißt; F Brinkmann; P Saladores; E Heidemann; G Ott; A Gerteis; M D Alscher; J Dippon; M Schwab; H Brauch; P Fritz Journal: Breast Cancer Res Treat Date: 2015-12-09 Impact factor: 4.872
Authors: Soo Youn Bae; Sangmin Kim; Jun Ho Lee; Hyun-Chul Lee; Se Kyung Lee; Won Ho Kil; Seok Won Kim; Jeong Eon Lee; Seok Jin Nam Journal: BMC Cancer Date: 2015-03-18 Impact factor: 4.430